Heparin-Dependent Platelet Activation Analysis Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current functional tests for diagnosing heparin-induced thrombocytopenia (HIT) require fresh platelets or blood from healthy donors, are not standardized, and involve complex methodologies, leading to variable results and difficulties in accessing healthy donors.
Innovation Solution
A method for analyzing heparin-dependent platelet activation in patients suspected of having HIT, using whole blood from the patient diluted in a buffer, with exogenous PF4 and a monoclonal antibody specific to polyanion-modified PF4, and varying heparin concentrations, followed by flow cytometry analysis to measure platelet activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If functional tests use fresh platelets or blood from healthy donors, then the sensitivity and specificity of HIT diagnosis can be achieved, but the complexity of the test procedure increases and access to healthy donors becomes difficult
Solution Approach 1:
The method uses the patient's own whole blood as both the test sample and the source of platelets, eliminating the need for healthy donors. The patient's blood serves the dual purpose of providing the diagnostic target and the cellular components needed for the assay, thereby simplifying the procedure and improving accessibility while maintaining diagnostic accuracy.
Solution Approach 2:
The invention creates a simplified model system using the patient's own blood instead of requiring complex preparations from healthy donors. By using the patient's whole blood directly in the assay, the method copies the essential functional elements needed for HIT diagnosis without requiring the complexity of healthy donor recruitment and platelet preparation.
2Measurement precision
If functional tests require platelet isolation and use healthy donor platelets, then the sensitivity of platelet activation detection can be improved, but the time required for testing increases and productivity decreases
Solution Approach 1:
The method performs preliminary preparation of the patient's whole blood sample in a way that preserves platelet functionality without requiring time-consuming isolation procedures. By using the patient's blood directly and pre-preparing it in the assay buffer, the method eliminates subsequent complex platelet isolation steps while maintaining the sensitivity needed for detecting platelet activation.
Solution Approach 2:
The invention extracts and eliminates the unnecessary steps of platelet isolation and healthy donor recruitment from the testing protocol. By taking out these complex preparatory steps and using the patient's whole blood directly, the method significantly reduces testing time and increases productivity while maintaining diagnostic precision through the use of flow cytometry for direct platelet activation detection.
3Reliability
If multiple functional tests are performed with different methodologies, then the comprehensive diagnosis of HIT can be achieved, but the variability in results increases and standardization becomes difficult
Solution Approach 1:
The invention creates a universal test system that can diagnose HIT using the patient's own whole blood, eliminating the need for multiple different methodologies. The single test system uses flow cytometry to detect platelet activation in the patient's blood, providing both comprehensiveness and consistency in diagnosing HIT without the variability introduced by different test protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for sensitive and specific diagnosis of HIT without the need for healthy donor samples, reduces variability in results, and provides standardized interpretation, thereby improving diagnostic accuracy and efficiency.
Implementation Method 1
The anti-polyanion-modified PF4 antibodies activate platelets via the FcγRIIa receptor
Implementation Method 2
platelet activation induced by antibodies directed against the polyanion-modified platelet factor 4 (PF4)
Implementation Method 3
followed by flow cytometry analysis to measure platelet activation
Implementation Method 4
the subsequent labeling of the platelet population and the specific labeling of activated platelets in said population
Data Source
AI summary
The present invention relates to a method for analyzing platelet activation induced by antibodies directed against the polyanion-modified platelet factor 4 (PF4), preferably directed against the PF4/heparin complex, as well as to a method of in vitro diagnosis of heparin-induced thrombocytopenia or of a diagnosis of exclusion of a heparin-induced thrombocytopenia in a patient, comprising specific steps.